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We examined the effects of the chemokine fractalkine (CX3CL1) on EPSCs evoked by electrical stimulation of Schaffer collaterals in
patch-clamped CA1 pyramidal neurons from rat hippocampal slices. Acute application of CX3CL1 caused a sustained reduction of EPSC
amplitude, with partial recovery after washout. CX3CL1-induced EPSC depression is postsynaptic in nature, because paired-pulse ratio
wasmaintained, amplitude distribution of spontaneous excitatory postsynaptic currents shifted to lower values, and whole-cell current
responses to AMPA were reversibly inhibited. EPSC depression by CX3CL1 is mediated by CX3CL1 receptor (CX3CR1), because CX3CL1
was unable to influence EPSC amplitude in CA1 pyramidal neurons from CX3CR1 knock-out mice. CX3CL1-induced depression of both
EPSC and AMPA current was not observed in the absence of afferent fiber stimulation or AMPA receptor activation, respectively,
indicating the requirement of sustained receptor activity for its development. Findings obtained from hippocampal slices, cultured
hippocampalneurons, and transfectedhumanembryonickidney cells indicate that aCa2-, cAMP-, andphosphatase-dependentprocess
is likely to modulate CX3CL1 effects because of the following: (1) CX3CL1-induced depression was antagonized by intracellular BAPTA,
8Br-cAMP, phosphatase inhibitors, andpertussis toxin (PTX); (2) CX3CL1 inhibited forskolin-induced cAMP formation sensitive toPTX;
and (3) CX3CL1 inhibited forskolin-induced Ser845 GluR1 phosphorylation, which was sensitive to PTX and dependent on Ca
2 and
phosphatase activity. Together, these findings indicate that CX3CL1 negativelymodulates AMPA receptor function at active glutamater-
gic synapses through cell-signaling pathways by influencing the balance between kinase and phosphatase activity.
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Introduction
The modulation of AMPA-type glutamate receptors (GluRs) is a
key event involved in many complex forms of synaptic plasticity,
including long-term depression (LTD) and potentiation (Kam-
eyama et al., 1998; Lee et al., 1998; Kullmann et al., 2000; Song
and Huganir, 2002). In the hippocampus, several endogenous
factors have been demonstrated to modify synaptic plasticity by
modulating the level of AMPA-type glutamate receptor expres-
sion or phosphorylation at postsynaptic sites (Carroll et al., 1999;
Lin et al., 2003;Wu et al., 2004).Many of these forms of plasticity
are activity dependent, indicating that specific conditions or pre-
vious synaptic history may alter their modulation of synaptic
function. Nevertheless, it is generally assumed that LTD can be
achieved by the activation of intracellular pathways that leads to
AMPA receptor dephosphorylation (Mulkey et al., 1993, 1994;
Lee et al., 1998), whereas long-term synaptic potentiation (LTP)
is driven by pathways that induce AMPA receptor phosphoryla-
tion (Malenka et al., 1989; Banke et al., 2000). It is believed that
second messengers may regulate synaptic plasticity acting on the
balance between kinase and phosphatase activity, and that
the phosphorylation of GluR1 subunit plays a pivotal role on the
mechanisms influencing this balance (Lee et al., 1998, 2000;
Tavalin et al., 2002).
Chemokines are small chemotactic molecules widely ex-
pressed throughout the CNS, where they contribute to the regu-
lation of cellular communication in the adult brain (Tran and
Miller, 2003) and of cell migration and differentiation during
development (Lu et al., 2002) and may exert neuroprotective
effects in different neurotoxic experimental conditions (Araujo
and Cotman, 1993; Meucci et al., 1998; Robinson et al., 1998;
Bruno et al., 2000; Limatola et al., 2000; Hatori et al., 2002; Deiva
et al., 2004; Krathwohl and Kaiser, 2004; Limatola et al., 2005).
Several examples illustrating the neuromodulatory potential of
chemokines and chemokine receptors in the CNS have been re-
ported. Specifically, chemokines may alter synaptic transmitter
release (Giovannelli et al., 1998; Meucci et al., 1998; Limatola et
al., 2000; Ragozzino et al., 2002), modulate the functional prop-
erties of ionic channels (Meucci et al., 1998; Lax et al., 2002; Oh et
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al., 2002) and promote the release of glutamate from astrocytes
(Bezzi et al., 2001). Among the chemokines, fractalkine
(CX3CL1) and its receptor CX3CR1 are highly expressed in hip-
pocampal neurons (Meucci et al., 1998, 2000; Hughes et al., 2002;
Tarozzo et al., 2003; Limatola et al., 2005), where they induce a
pertussis toxin (PTX)-sensitive increase of intracellular Ca2
(Meucci et al., 2000) and reduce both spontaneous glutamate
release (Meucci et al., 1998) and postsynaptic glutamatergic cur-
rents (Limatola et al., 2005). We wondered whether, in hip-
pocampal tissue, CX3CL1 could function as an endogenousmod-
ulator of synaptic plasticity. Here, we show that in the rat
hippocampus, CX3CL1 negatively modulates EPSCs at Schaffer
collateral-CA1 synapses acting at postsynaptic sites of active syn-
apses through mechanisms involving CX3CR1, reduces postsyn-
aptic AMPA-evoked currents, and triggers signaling pathways
that favor the reduction of Ser845 GluR1 phosphorylation.
Materials andMethods
Slice preparation. Hippocampal slices were prepared from 14- to 22-d-
old Sprague Dawley rats or homozygous wild-type (wt), knock-out
(KO), and heterozygous littermates derived from breeding between het-
erozygous CX3CR1-KOmice on the C57BL/6 background (Haskell et al.,
2001). All experiments followed international guidelines on the ethical
use of animals from the European Communities Council Directive of 24
November 1986 (86/609/EEC). Rats were decapitated under halothane
anesthesia, and whole brains were rapidly removed and incubated in
chilled artificial CSF (ACSF) for 15 min. Transverse hippocampal slices
(250 m) were cut at 4°C, using a Vibratome (DSK, Dosaka EM, Kyoto,
Japan). Before use, slices were maintained for at least 1 h at room tem-
perature (22–25°C) in oxygenated (95% O2-5% CO2) ACSF, containing
the following (inmM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 2
CaCl2, 1 MgCl2, and 10 glucose, pH 7.35. All recordings were performed
at room temperature on slices submerged in ACSF in the recording
chamber. The ACSF was perfused at a rate of1 ml/min.
Patch-clamp recordings. Neurons were visualized at 640 with No-
marski optics with an upright Zeiss (Thornwood, NY) Axioscopemicro-
scope. Patch-clamp recordings were obtained using glass electrodes (3–4
M) filled with the following (in mM): 140 CsCl, 2 MgCl2, 10 HEPES, 2
MgATP, 0.2–20 BAPTA (5 mM where not otherwise indicated; pH 7.3,
with CsOH). Bicuculline methyl-chloride (10 M), unless otherwise in-
dicated, was routinely added to the bath solution to block GABAA recep-
tors, and recordings started at least 10 min after bicuculline addition to
allow complete GABAergic block. Neurons were clamped at 70 mV,
unless otherwise indicated. Membrane currents, recorded with a patch-
clamp amplifier (Axopatch 200A; Molecular Devices, Foster city, CA),
were filtered at 2 kHz, digitized (10 kHz), and acquired with LTP114
software package (courtesy of W. R. W. Anderson, Bristol University,
UK) or Clampex8 software (Molecula Devices). Data were analyzed off-
line either with LTP114 and/or Clampfit 9 (Molecular Devices).
Evoked synaptic currents. EPSCs were evoked in CA1 pyramidal neu-
rons by electrical stimulation with theta glass tubes pulled to a final tip
diameter of 10–20 m and filled with external solution. Stimulating
electrodes were placed in the stratum radiatum to activate the Schaffer
collateral pathway projecting to CA1. EPSCs were evoked by stimulating
at 5–50 V for 150–300 s every 4 s in the presence of bicuculline. The
stimulus was adjusted to evoke EPSCs in the range 15–50 pA. Recorded
EPSCs were routinely averaged over 1 min (n 15) to analyze the time
course of EPSC amplitude. Stable EPSCs were monitored for at least 10
min before applying CX3CL1 and successively monitored during slice
exposure to CX3CL1. Closely spaced consecutive stimuli (50ms interval)
were used, and paired-pulse ratio was calculated as the ratio between the
amplitude of the responses evoked by the second stimulus (P2) over the
first (P1; P2/P1). The stability of the patch was checked by repetitively
monitoring the input and series resistance during the experiment, and
recordings were discarded when any of these parameters changed by
10%.
Drugs and application procedures. CX3CL1 (rat, Calbiochem, La Jolla,
CA; human, Peprotech, Rocky Hill, NJ), bicuculline (Tocris Cookson,
Avonmouth, UK), tetrodotoxin (TTX), D-2-amino-5-
phosphonopentanoic (D-APV), forskolin (FSK; stock solution 12 mM in
DMSO), and 8Br-cAMP (stock solution 100 mM in H2O) were usually
applied to the slice by bath perfusion. Because no substantial differences
between rat and human CX3CL1 were detected, all experiments here
reported were performed with rat CX3CL1, except for mouse prepara-
tions, where human CX3CL1 was used. Unless otherwise indicated, the
CX3CL1 concentration routinely used was 2 nM. To activate postsynaptic
glutamate receptors, AMPA (Tocris Cookson) or glutamate were deliv-
ered together with cyclothiazide (50 M; Tocris Cookson) by pressure
application (5–15 psi, 10–100 ms; Picospritzer II, General Valve, Fair-
field, NJ) from glass micropipettes positioned above the slice over the
soma of the recorded neuron. In some experiments, AMPA applications
were delivered in a Ca2-free solution (0 Ca2/1 mM EGTA) while su-
perfusing slices with standard medium. When necessary, calyculin A
(Calbiochem), cyclosporin A (Alexis Biochemicals, SanDiego, CA), oka-
daic acid, thapsigargin, 8Br-cAMP, ATPS, and PTX were added to the
patch pipette solution. PTX, stocked at 200 g/ml, was activated in 10
mM dithiothreitol at 37°C for 15 min, diluted at 10 g/ml in the pipette
solution containing 20 mM nicotinic acid adenine dinucleotide, and fur-
ther diluted 1:10 to a final concentration of 1g/ml after 10min (Xie and
Lewis, 1997). In all experiments based on intracellular dialysis, we waited
for 20–30min to attain intracellular drug diffusion. Control experiments
showed that EtOH and DMSO, at their final concentrations in the intra-
cellular solution (never higher than 1:1000 and 1:10000, respectively), or
dithiothreitol plus nicotinic acid adenine dinucleotide did not alter the
pattern of glutamatergic currents. Unless otherwise indicated, all drugs
were purchased from Sigma Italia (Milan, Italy).
Electrophysiological data analysis.Data are presented as mean SEM;
statistical significance was assessed with paired t test, unless otherwise
specified. Dose–response curves were fitted with a Hill equation (Origin
software;Microcal Software, Northampton,MA). Spontaneous postsyn-
aptic currents were acquired by pClamp software into separate files (5
min duration) and pooled during analysis by Clampfit 9.2 software. Am-
plitude distribution of EPSCs was fitted by a Gaussian (Origin software).
Slice preparation for biochemical experiments.Hippocampal slices, pre-
pared as described above, were collected in ACSF, transferred to a
submersion-type holder chamber, and incubated at room temperature in
ACSF bubbled with 95% O2 and 5% CO2 for 1 h. The slices were then
transferred to a 24-well plate with mesh inserts (Corning, Corning, NY);
each well was filled with ACSF. The multiwell plates were supplied with
humidified oxygenated atmosphere (95% O2, 5% CO2) and placed in a
30°C water bath. The slices were left to equilibrate for 1 h before the
experiment. The slices were gently transferred by using the mesh inserts
to a well containing ACSF (control), FSK (1 M), or 12-O-
tetradecanoylphorbol-13-acetate (TPA; 1M) in the presence or absence
of CX3CL1 (100 nM) for 15 min. Reactions were blocked in ice-cold
ACSF, and slices were quickly frozen on dry ice and stored at 80°C.
Homogenates of hippocampal slices were prepared by sonicating the
slices in resuspension buffer (RB) consisting of the following (inmM): 10
Na phosphate, pH 7.0, 100 NaCl, 10 Na pyrophosphate, 50 NaF, 1 Na
orthovanadate, 5 EDTA, 5 EGTA, 1 M okadaic acid, and 10 U/ml apro-
tinin for 30 s. The homogenates were centrifuged at 12,000 g for 5min,
and the crude membrane pellets were resuspended in RB buffer. Protein
concentration was determined by BCA protein assay (Pierce, Rockford,
IL);20g of proteins per lane were loaded onto a SDS-polyacrylamide
gel and analyzed by Western blotting with antibodies specific for
phospho-GluR1 Ser845 or Ser831 (Upstate Biotechnology, Lake Placid,
NY), and actin (Sigma). Immunoreactivity was detected by chemilumi-
nescence. Specific bands on chemiluminescence films were quantified by
densitometry with Sigma Gel Software (Jandel Scientific, Erkrath, Ger-
many). To test the effect of phosphatase inhibitors, once transferred to a
24-well plate with mesh inserts in a humidified oxygenated chamber
(95% O2, 5% CO2, 30°C), the slices were left to equilibrate with ACSF
alone or together with calyculin A (200 nM) for an additional 90 minutes
before proceeding with drug treatment (FSK with/without CX3CL1).
Cell transfection.Human embryonic kidney 293 (HEK) cells were rou-
tinely grown inDMEMplus 10% fetal bovine serum.Cells were plated on
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poly-L-lysine-coated 35 mm dishes and transiently transfected 24 h later
with cDNA encoding humanGluR1 (flip-variant; ATCC,Manassas, VA)
and human CX3CR1 (Limatola et al., 2005) using either a standard
calcium-phosphate procedure or Lipofectamine 2000 (Invitrogen, Carls-
bad, CA). Routinely, cells were used for electrophysiological experiments
48 h after transfection.
Hippocampal neuronal cultures. Hippocampal neuronal cultures were
prepared from 2-d-old [postnatal day 2 (P2)] Wistar rats. Briefly, after
careful dissection from diencephalic structures, the meninges were re-
moved and tissues were chopped and digested in 0.25% trypsin for 15
min at 37°C. Cells were dissociated and plated at a density of 4.5 105 in
poly-L-lysine-coated plates in MEM, with Earl’s salts and GLUTAMAX
containing 10% dialysed and heat-inactivated fetal bovine serum, 100
g/ml gentamycin, and 25 mM KCl, and maintained at 37°C in 5% CO2.
After 24 h, cytosine--D-arabinofuranoside was added at a final concen-
tration of 10 M to prevent glial cell proliferation. Cells were used for
experiments after 7–8 d.
Cell stimulation and Western blot analysis. HEK cells were serum
starved for 16 h, incubated in Locke’s buffer (in mM: 154 NaCl, 5.6 KCl,
3.6 NaHCO3, 2.3 CaCl2, 1 MgCl2, 5.6 glucose, buffered with 5 HEPES,
pH 7.4) for 2 h and stimulated for 30 min with FSK (5.2 M) alone or
together with CX3CL1 (100 nM). Cultured hippocampal neurons were
incubated for 2 h in Locke’s buffer and stimulated for 5minwith FSK (5.2
M) alone or together withCX3CL1 (100 nM).When necessary, cells were
pretreated with PTX (1 g/ml; 2 h), BAPTA/AM (5 M; 1 h), or cyclo-
sporin A (1 M; 1 h). Cells treated with BAPTA were rinsed twice in
Ca2-free Locke’s buffer with 2 mM EGTA and 3 mM MgCl2, once in
Ca2-free Locke’s buffer containing 3 mM MgCl2, and then stimulated
in the last buffer containing 5MBAPTA/AM.Corresponding cell lysates
were run on SDS-polyacrylamide gel and analyzed for GluR1 Ser845
phosphorylation as above.
Measurement of cAMP concentration. Eight-day-old cultured hip-
pocampal neuronswere starved for 2 h in Locke’s buffer, incubated for 30
min with IBMX (0.5 mM), and stimulated with FSK (5.2 M) in the
presence or the absence of CX3CL1 for different time, from 5 to 30 min.
Incubation was terminated by adding a solution of ice-cold 30% trichlo-
roacetic acid, and cells were scraped and centrifuged for 30 min at
15,000  g. Supernatant was neutralized by three washes with water-
saturated diethyl ether, and NaHCO3 addition, lyophilized and reconsti-
tuted with H2O for cAMP quantification with a commercial radioactive
assay (GE Healthcare, Buckinghamshire, UK). PTX and BAPTA treat-
ment were performed as described above.
Phosphatase assay. Eight-day-old cultured hippocampal neurons were
starved for 2 h in Locke’s buffer and stimulated with FSK (5.2 M) in the
presence or in the absence of CX3CL1 for 15 min. Cells were lysed in
buffer containing 20mMHEPES, pH 7.4, 50mMNaCl, 0.2mMEGTA, 0.5
mMDTT, 0.3% Triton X-100, and protease inhibitors centrifuged for 1 h
at 20,000 g, and supernatant was analyzed for protein phosphatase 2B
(PP2B) activity after removal of endogenous phosphate with a Sephadex
G-25 resin column (Promega, Madison, WI). Phosphatase assay was
performed on 100M phosphopeptide RRA(pT)VA in buffer containing
the following: 50 mM imidazole, pH 7.2, 0.2 mM EGTA, 10 mM MgCl2, 1
mM NiCl2, 50 g/ml calmodulin, and 0.02% -mercaptoethanol for 30
min at 30°C, and reaction was blocked by a Molybdate solution and free
phosphate quantified measuring absorbance at 630 nm with a plate
reader.
Results
CX3CL1 reduces EPSC amplitude through the activation
of CX3CR1
Whole-cell recordings of EPSCs were performed in CA1 pyrami-
dal neurons from acute rat slices while repeatedly stimulating
Schaffer collateral axons (0.25 Hz). Superfusion with CX3CL1
(6–12min) caused a reduction in EPSCpeak amplitude (Fig. 1A)
without any obvious effect on resting membrane conductance or
holding current. CX3CL1-induced EPSC amplitude depression
developed within 5 min of CX3CL1 application with maximal
depression (to 68  8%; n  9) observed at 10 min and was
followed by partial recovery (to 85  4% within 30 min of che-
mokine withdrawal) with a few exceptions, where full recovery
was observed (Figs. 1A, 4B). This depression was induced by
CX3CL1 at a concentration as low as 0.2 nM and was dose depen-
dent (Fig. 1B).
We then examined whether the action of CX3CL1 on EPSC
amplitude was effectively mediated through CX3CR1 by per-
forming the same experiments in wt and CX3CR1 KO mice
(Haskell et al., 2001). CX3CL1 reduced the average EPSC ampli-
tude to 64 12% (n 6) (Fig. 2A,B) in pyramidal neurons of wt
mice. Notably, the CX3CL1 effect was sustained considerably
longer after washout in mouse slices compared with rat slices.
The CX3CL1 effect was slightly attenuated in slices from het-
erozygous mice (to 77  15%; p  0.1; n  7) (Fig. 2B) and
absent in slices from CX3CR1-KO mice (to 100 8%; p 0.41;
Figure 1. CX3CL1 reduces the amplitude of evoked EPSCs in CA1 pyramidal neurons. A, Top
left, Sample traces of EPSCs (average of 15 events over 1 min) recorded before, after 10 min of
chemokine application, and 30 min after washout, as indicated. A, Top right, Superimposed
enlarged traces in control and CX3CL1; note the absence of changes in the input resistance. A,
Bottom, Time course of the current peak amplitude in the same cell. Circles represent averages
as indicated previously. Horizontal bar, Chemokine application. Note full recovery after wash-
out. The concentration of CX3CL1 here and in subsequent figures, unless otherwise indicated, is
2 nM. B, CX3CL1 dose-EPSC amplitude relationship. The filled circles, here and in subsequent
figures, refer to means SEM of single determinations on separate slices (n 5–14). The
calculated IC50 value for CX3CL1 is 1 nM with nH 1.
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n  9) (Fig. 2), indicating that CX3CL1-induced EPSCs depres-
sion is mediated through CX3CR1 activation.
We also conducted experiments to see whether endogenous
CX3CL1 could affect glutamatergic synaptic transmission in our
slices. Western blot analysis revealed that CX3CL1 was expressed
at levels comparable with those observed in cultured hippocam-
pal neurons (data not shown) (Limatola et al., 2005). We then
tested the effect of an anti-CX3CL1 antibody (Ab) on glutamater-
gic transmission. Pretreatment with anti-CX3CL1 Ab (TP 203, 2
g/ml, 20 min superfusion; Torrey Pines Biolabs, Houston, TX)
suppressed the effects of exogenous CX3CL1 on evoked synaptic
transmission (n 3) (data not shown) but did not produce any
obvious change in the control evoked response (n 4) (data not
shown), suggesting that endogenous CX3CL1 does not contrib-
ute significantly to the modulation of glutamatergic neurotrans-
mission under the conditions used in our studies.
CX3CL1 acts postsynaptically on pyramidal neurons
It has been reported previously that CX3CL1 modulates both
glutamatergic spontaneous synaptic currents (Meucci et al.,
1998) andAMPA-activated currents (AMPA currents) (Limatola
et al., 2005) in cultured hippocampal neurons. To determine
whether CX3CL1 modulates glutamatergic neurotransmission
via presynaptic or postsynapticmechanisms, we analyzed paired-
pulse facilitation of synaptic responses and spontaneous excita-
tory events in rat pyramidal neurons from hippocampal slices.
First, we analyzed the paired-pulse ratio of the responses
evoked by two closely spaced stimuli. Paired-pulse facilitation
was 136  20% (n  7) and persisted after 10 min CX3CL1
application (139 21%; n 7; p 0.05) before washout. Am-
plitudes of both EPSCs decreased to a similar degree (first EPSC,
to 67 6%, p	 0.01; second EPSC, to 68 5%, p	 0.01) (Fig.
3A,B). These findings indicate that the presynaptic site is proba-
bly not involved in EPSC depression by CX3CL1 (Dobrunz and
Stevens 1997). Next, we analyzed the distribution of spontaneous
EPSC (sEPSC) amplitudes after chemokine treatment. sEPSCs
exhibited a mean amplitude of18.9 6.1 pA and frequency of
2.7  0.3 Hz (n  7) and were glutamatergic in nature, being
blocked by CNQX (10 M) (data not shown). In four neurons,
after CX3CL1 treatment (2 nM; 10 min), the mean amplitude of
sEPSCs was significantly reduced from15.2 2.1 to11.3
1.4 pA ( p	 0.05), the frequency (2.3 0.3 Hz) remaining stable
(data not shown). The analysis of sEPSC amplitude distribution
showed a shift toward lower amplitude after CX3CL1 treatment
(Fig. 3C,D). Together, these findings suggest that postsynaptic
glutamatergic receptors are involved in the synaptic depression
induced byCX3CL1 treatment. Interestingly, CX3CL1was unable
to reduce the sEPSC amplitude when the frequency of spontane-
ous sEPSCs was relatively low, because CX3CL1 did not alter
either the frequency or the amplitude of sEPSCs in five neurons
displaying a frequency	0.5 Hz (data not shown).
CX3CL1-induced EPSC depression is modulated by Ca
2
It has been reported previously that CX3CL1 can elicit a transient
increase in intracellular Ca2 (Meucci et al., 2000) and that che-
lating intracellular Ca2 in hippocampal cultures blocks
CX3CL1-dependent inhibition of glutamatergic currents (Lima-
tola et al., 2005). To investigate whether Ca2 modulates
CX3CL1-induced depression of EPSC amplitude, we performed
experiments under various concentrations of the Ca2 chelator
BAPTA in the patch pipette recording solution. When BAPTA
was increased from 5mM (standard solution) to 20 mM, CX3CL1
failed to significantly affect EPSC amplitude (to 91  3%,
mean SEM; p 0.61, one-way ANOVA; n 4) (Fig. 4A, open
circles). Conversely, when BAPTA was decreased to 1 mM, EPSC
amplitude was reduced to 60  3% before washout (Fig. 4A,
black triangles) ( p  0.03, one-way ANOVA; n  9), and this
depression was maintained even after washout. These findings
suggest that the strength of cytosolic Ca2 buffering regulates the
efficacy of CX3CL1 in depressing the EPSC amplitude.
To see whether the efficacy of CX3CL1 in depressing EPSCs
could depend on the kinetics of Ca2 buffering, we performed
experiments with the slowCa2 chelator EGTA. CX3CL1 applied
to pyramidal neurons dialyzed with EGTA-containing solution
(EGTA 20 mM) reduced the EPSC amplitude during 10 min ap-
plication (to 67 9%; n 4; p 0.03; not illustrated), indicating
that slow Ca2 chelators were unable to regulate the efficacy of
CX3CL1 in inducing synaptic depression.
To identify the source of Ca2 involved in the CX3CL1-
induced synaptic AMPA receptor modulation, we dialyzed neu-
rons with the Ca2-ATPase inhibitor thapsigargin (1 M) to re-
duce cytosolic Ca2 mobilization from intracellular stores. We
found that, with thapsigargin in the patch pipette solution,
CX3CL1 was still able to reduce EPSC amplitude with the same
efficacy as in control neurons (to 75 9%; n 5; p 0.05) (data
not shown). Together, these findings suggest that Ca2 entry
rather than cytosolic Ca2 mobilization is involved in the
CX3CL1 effect observed.
BecauseCa2 entry at glutamatergic synapses is primarilyme-
Figure 2. CX3CL1-induced EPSC depression is absent in CX3CR1-KOmice.A, Sample traces of
EPSCs recorded in CX3CR1-KO mice (left,/) and wt littermates (right,/) before and
after CX3CL1 application, as indicated. B, Time course of CX3CL1 effect on EPSC amplitude in
hippocampal CA1 neurons from CX3CR1-KOmice (▫; n 9),wt (F; n 6) and heterozygous
littermates (half-filled circle; n 7). Here and in subsequent figures, current amplitudes are
normalized to current recorded before chemokine application. The star represents 100%
current.
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diated through NMDA receptors, we in-
vestigated whether the activation of
NMDA receptors could contribute to the
effects of CX3CL1 on EPSC amplitude.
The NMDA receptor blocker D-APV (40
M) was applied to pyramidal cells that
were subsequently treated with CX3CL1.
Pyramidal neurons exposed to D-APV
were still responsive to CX3CL1 (average
depression to 70 7%; n 6; p 0.006;
10 min CX3CR1 treatment) (data not
shown), indicating that the EPSC depres-
sion was not dependent on NMDA recep-
tor function.
CX3CL1-induced EPSC depression is
regulated by synaptic activity
Because under our experimental condi-
tions excitatory synaptic activity modu-
lates cytosolic Ca2 level increasing Ca2
influx at active synapses (Yuste et al.,
1999), we investigated whether synaptic
activity could influence the CX3CL1-
induced EPSC depression. To test for an
effect on synaptic activity, we first ob-
tained stable EPSC responses from a pyra-
midal neuron, thenwe superfused the slice
with CX3CL1-containing medium while
Schaffer collateral stimulation was inter-
rupted, and finally we resumed the electri-
cal stimulation 2 min after chemokine
withdrawal. Under these conditions, we
found that CX3CL1 failed to inhibit EPSCs
with the EPSC amplitude remaining un-
changed (to 98  11%; n  9) (Fig. 4B,
open squares) when compared with stim-
ulated neurons (to 67 6%; p 0.04; n
9) (Fig. 4B, closed circles). These findings
indicate that CX3CL1 exerts an inhibitory
action on hippocampal neurons in aman-
ner depending on synaptic activity.
CX3CL1 inhibits AMPA currents
To gather additional evidence for CX3CL1 action at a postsynap-
tic site, we applied AMPA (10–100 M) onto CA1 hippocampal
pyramidal neurons, because under our experimental conditions,
synaptic currents were mediated mainly through AMPA/KA re-
ceptors (Hestrin et al., 1990). As shown in Figure 5A, brief AMPA
applications (10–100 ms) in the presence of TTX (1 M) and
bicuculline (10M) induced inward currents (range, 55–550 pA).
These currents were completely abolished in the presence of
CNQX (10M; n 3) (data not shown) and thusmediated by the
activation of postsynaptic AMPA/KA receptors. We found that
the amplitude of AMPA currents was reversibly depressed by
CX3CL1 application to 79 5% (n 11; p 0.001) after 10min
CX3CL1 treatment and recovered to 98 3% after washout (n
11) (Fig. 5A). Interestingly, CX3CL1-induced inhibition of
AMPA currents was dependent on the current amplitude, with
larger currents more strongly depressed by CX3CL1 (Fig. 5B).
Because the repetitive stimulation of synaptic AMPA recep-
tors could influence CX3CL1-induced EPSC depression, being
blocked by absence of synaptic activity (Fig. 4B), experiments
were performed to determine whether the AMPA current ampli-
tude depression could be influenced by repetitive AMPA receptor
activation. It was found that CX3CL1 application to pyramidal
neurons, when it was not accompanied by AMPA receptors stim-
ulation with exogenous AMPA, was unable to depress AMPA
currents at the end of CX3CL1 application. In fact, after CX3CL1
treatment and washout (2 min), the amplitude of AMPA re-
sponses was unchanged compared with the control (102 17%;
n  5; p  0.9) (Fig. 5C) with only a slight transient depression
seen at10 min washout.
Finally, a number of experiments were performed to see
whether AMPA current depression was dependent on Ca2.
With 0.2 mM BAPTA in the recording patch pipette, AMPA cur-
rents ranging from61 to217 pA were significantly depressed
by CX3CL1 application (10 nM) with an irreversible current run-
down (Fig. 6, closed circles). Conversely, when similar AMPA
applications were performed in a Ca2-free solution (0 Ca2/1
mM EGTA; current amplitudes from 70 to 240 pA), slice
superfusion with CX3CL1 did not cause a reduction of AMPA
currents (Fig. 6, open squares). Together, these findings indicate
that Ca2 entry is required for the CX3CL1-induced depression
Figure 3. CX3CL1-induced depression is postsynaptic. A, Superimposed traces (top) of EPSC responses (average as in Fig. 1A)
evoked in a CA1neuronbypaired-pulse stimulation (50ms interval) in control andafter 10min applicationof CX3CL1, as indicated.
Scaled traces (bottom) in the presence of CX3CL1, showing no difference in paired-pulse ratio. B, Histogram of EPSC amplitude
showing theCX3CL1-inducedaveragedepressionof EPSCs evokedby the first (P1,white column) and the second (P2, gray column)
pulse. C, Histogram of the spontaneous EPSC amplitudes recorded before (empty columns) and after (dashed columns) 10 min
CX3CL1 treatment, as indicated by arrows, fromapyramidal neuron. Distributions fitted to Gaussian equations (control data, X0
21.5 pA, 10.5; CX3CL1, X0 17.9 pA, 8.2). Traces (inset) represent EPSCs (average of 30 events) before and at the end
of CX3CL1 treatment, as indicated. D, Cumulative amplitude distribution of EPSCs in control and CX3CL1 from the same neuron as
in C. Note the shift to lower amplitudes in the presence of CX3CL1.
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of AMPA currents generated by the activation of extrasynaptic
AMPA receptors in analogy with findings reported above for
synaptic AMPA receptors.
CX3CL1-induced EPSC depression is dependent on Gi-
mediated cAMP reduction
CX3CR1 is coupled to Gi- and Gz-proteins in natural killer cells
(Al-Aoukaty et al., 1998), and CX3CL1 effects on Ca
2 transients
and cell survival are abolished by PTX in hippocampal neurons
(Meucci et al., 2000; Limatola et al., 2005). Thus, experiments
were performed in hippocampal slices to determine whether
PTX, a selective inhibitor of the i subunits of Gi, was able to
block CX3CL1-induced EPSC depression. It was found that, in
cells internally dyalized with activated PTX (1g/ml), EPSC am-
plitude remained stable after CX3CL1 stimulation (15min; 109
19%; p 0.66;n 10; five rats), indicating thatCX3CL1-induced
EPSC depression was mediated through signaling pathways
downstream of Gi activity (data not shown). To identify the sig-
naling pathway involved, intracellular levels of cAMP were mea-
sured in hippocampal cultures exposed to the adenylate cyclase
(AC) stimulator FSK (5 M) in the presence or absence of
CX3CL1 (100 nM) for different time, up to 30min. Results, shown
in Figure 7A (left), demonstrate that CX3CL1 significantly re-
duced FSK-induced cAMP accumulation, indicative of AC inhi-
bition via Gi activation, and that this effect is already evident after
5 min stimulation. CX3CL1-mediated cAMP reduction was
blocked byPTX treatment andwas independent ofCa2, because
it was insensitive to treatment with BAPTA/AM (Fig. 7A, right).
To investigate whether the CX3CL1-induced reduction of in-
tracellular cAMP levels could contribute to CX3CL1-induced
EPSC depression, we performed electrophysiological recordings
in the presence of either FSK or 8Br-cAMP, drugs that increase
cAMP signaling by activating AC and mimicking cAMP, respec-
tively. As expected, exposure of slices to FSK (5 M; 20–40 min)
caused an increase in the amplitude of evoked EPSCs (to 220 
20% after 40 min, n  10) (Chavez-Noriega and Stevens, 1994;
Sokolova et al., 2006). CX3CL1 caused a reversible decrease in
EPSC amplitude that was significantly greater in the presence (to
52 8%; n 10) (Fig. 7B, closed circles) than in the absence of
FSK (to 77 4%; p 0.04, one-way ANOVA; n 6) (data not
shown). As in the absence of FSK, this effect was not observed
when Schaffer collateral stimulation was interrupted (n  5)
(data not shown).
Conversely, when slices were superfused with a stable mem-
brane permeant cAMP analog, 8Br-cAMP (100 M), and then
cotreated with CX3CL1 (12 min), an analogous depression of
EPSC was not observed (to 110 8%; p 0.61; n 6) (Fig. 7B,
open squares). Similar results were obtained in four cells inter-
nally perfused with 8Br-cAMP (100 M) (data not shown). To-
gether, these findings indicate that the effects of CX3CL1 onEPSC
are stringently related to a Gi-dependent reduction of cAMP
formation.
CX3CL1-induced EPSC depression is dependent on
association of protein kinase A to GluR1
Because we observed that CX3CL1-mediated depression of EPSC
relied on a Gi-dependent reduction of cAMP formation, we in-
vestigated whether protein kinase A (PKA) anchoring to the
complex AKAP-GluR1 was involved in CX3CL1 action. Cells in-
ternally dialyzed with Ht31 (1 M), a competitive antagonist of
PKA anchoring (Tavalin et al., 2002), did not exhibit any obvious
CX3CL1-mediated EPSC depression during 15 min treatment
(98  7%, p  0.8; n  6) (data not shown). In contrast, EPSC
depression occurred normally when Ht31 was substituted by the
inactive prolinated peptide (Ht-31p, 1M). We concluded that a
physical association of PKA to GluR1 was required for the devel-
opment of CX3CL1-mediated EPSC depression.
CX3CL1 stimulation reduces GluR1 phosphorylation
at Ser845
The phosphorylation of GluR1 by cAMP-dependent PKA at
Ser845 and by calcium calmodulin-dependent protein kinase II
(CaMKII) and protein kinase C (PKC) at Ser831 has been asso-
ciated with modulatory effects on AMPA receptor function.
GluR1 phosphorylation at Ser845 increases channel opening
probability (Banke et al., 2000), whereas phosphorylation at
Ser831 enhances channel conductance (Derkach et al., 1999). In
addition, changes in the phosphorylation level at both Ser845 and
Ser831 are associated with the long-termmodulation of synaptic
AMPA receptors (Lee et al., 1998, 2000). Thus, we investigated
whether CX3CL1-induced AMPA-current depression could be
associated with a change in the phosphorylation of GluR1 at
Ser845 and/or Ser831. We found that CX3CL1 clearly reduced
Ser845 GluR1 phosphorylation in hippocampal slices stimulated
Figure 4. CX3CL1-induced EPSC depression is Ca
2 and activity dependent. A, Left, Time
course of CX3CL1 effects on EPSCs in the presence of the Ca
2 chelator BAPTA at 20mM (E) or
1 mM () in the patch pipette solution, as indicated. Symbols represent mean values of four to
nine experiments. A, Right, Sample EPSCs traces recorded in the presence of 20 mM (E) and 1
mMBAPTA () before and10minafter CX3CL1application, as indicated.B, Time courseof EPSCs
after CX3CL1 application to stimulated (control, F; n 9) and nonstimulated (▫; n 9)
pyramidal neurons. Application of CX3CL1 is as indicated.
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with FSK (to 55.6 2.2%; p	 0.001; n
11) (Fig. 8A, left) to increase the basal level
of GluR1 phosphorylation. No obvious ef-
fect of CX3CL1 was seen on basal Ser845
phosphorylation (data not shown). Inter-
estingly, the phosphorylation of Ser831 in-
duced by the protein kinase C activator,
TPA, was not obviously reduced by
CX3CL1, with even a slight increase being
eventually observed (n  3) (Fig. 8A,
right). Analogous results were obtained in
HEK cells transiently expressing GluR1
and CX3CR1 (to 62.4  4%; p 	 0.001;
n  10) (Fig. 8B, top, one representative
experiment), where CX3CL1 (10 nM) was
able to induce reversible AMPA current
depression (to 60  8%; p  0.002; n 
10) (Fig. 8B, bottom) and in cultured rat
hippocampal neurons (to 66.7 3%; p	
0.01; n 4) (Fig. 8C, top, one representa-
tive experiment), where CX3CL1 was able
to reduce AMPA-mediated currents (Li-
matola et al., 2005).
We next investigated whether PTX or
the intracellular Ca2 chelator
BAPTA/AM couldmodulate the CX3CL1-
induced reduction of Ser845 phosphoryla-
tion, as was the case for the CX3CL1-
induced EPSC depression. Hippocampal
cultured neurons were exposed to
BAPTA/AM (5 M; 1 h) or PTX (1 g/ml;
2 h) and then treated with FSK in the pres-
ence or absence of CX3CL1. No reduction of phosphorylation
was observed in the presence of BAPTA-AM (to 131  12.4%;
p 0.1; n 3) or PTX (to 147 27%; p 0.2; n 3), as shown
in the histogram in Figure 8C (bottom). Together, these data
suggest that CX3CL1-induced reduction of Ser845 phosphoryla-
tion is mediated by a Gi-dependent reduction of adenylyl cyclase
activity and thereby PKA activity. In addition, CX3CL1-induced
reduction of Ser845 phosphorylation is dependent on intracellu-
lar Ca2.
Phosphatase inhibitors block both CX3CL1-induced EPSC
depression and reduction of Ser845 phosphorylation
Because the phosphorylation state of Ser845GluR1 results from a
delicate balance between protein kinase A and phosphatase activ-
ity (Lee et al., 2000), we investigated the role of phosphatases in
CX3CL1-mediated effects.
We performed several experiments in which ATPS was sub-
stituted for ATP in the intracellular solution. ATPS promotes
irreversible substrate thio-phosphorylation (Eckstein, 1985) and
blocked CX3CL1-induced EPSC depression (to 99  12%; p 
0.96; n 6) (data not shown), indicating that substrate dephos-
phorylation was necessary for EPSC depression. Subsequently,
we found that calyculin A (100 nM in the patch pipette) and
okadaic acid (1 M, 1 h in the external solution or in the patch
pipette), both potent blockers of PP1/2A (Bialojan and Takai,
1988; Herzig and Neumann, 2000; Winder and Sweatt, 2001),
abolished CX3CL1-induced AMPA current depression (calyculin
A, to 96 2%; n 5; p 0.2) (Fig. 9) (okadaic acid, to 96 4%,
n 8, p 0.24 in the external solution and to 114 12%, n 4,
p  0.3, in the pipette) (data not shown). We found similar
results with cyclosporin A, a specific PP2B/calcineurin inhibitor
(Unno et al., 1999) (250 M, 1 h superfusion, or 1 M in the
pipette), which fully inhibited CX3CL1-induced AMPA current
amplitude depression (to 93  4%, n  8, p  0.28, in external
medium, to 104  5%, n  4; p  0.4, in the pipette) (data not
shown). Considered together, these findings indicate that func-
tional protein phosphatases are required for CX3CL1-dependent
AMPA current depression.
Figure 5. CX3CL1 reduces AMPA current responses in CA1 neurons. A, Top, Current responses to AMPA applications () in
control, 10 min after CX3CL1 application, and 15 min after chemokine washout, as indicated. Arrowheads signal agonist applica-
tions (AMPA, 10M; 100ms). A, Bottom, Time course of CX3CL1-induced depression of postsynaptic AMPA currents. B, Relation-
ship between AMPA current peak amplitude and CX3CL1-induced depression. Data fitted to a single exponential, y y0
A (x /  ). Note reduced CX3CL1-induced depression at lower AMPA current amplitudes. C, Time course of AMPA currents after
CX3CL1 application to nonstimulated pyramidal neurons (n 5). Application of CX3CL1, as indicated. The dashed line signals the
100% value. Note that the CX3CL1-induced depression of AMPA current is activity dependent.
Figure6. CX3CL1-induceddepression of AMPA currents is suppressed in Ca
2-free solution.
Time course of the effect of CX3CL1 on the amplitude of AMPA-evoked currents (100M; 100
ms) recorded in CA1 pyramidal neurons (0.2 mM BAPTA in intracellular patch pipette solution).
F, AMPA applications in normal external solution (n 11).▫, Applications of AMPA dissolved
in Ca 2-free solution (n8). Note that, in all experiments, CX3CL1dissolved in standardACSF.
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As expected, phosphatase inhibitors reduced the effects of
CX3CL1 on Ser845 phosphorylation. After preincubation with
calyculin A (200 nM; 90min), hippocampal slices were treated for
15min with FSK (1M) alone or together with CX3CL1 (100 nM)
in the continuous presence of calyculin A. Under these condi-
tions, CX3CL1 was less effective in reducing FSK-induced Ser845
phosphorylation (to 88.3  1.7%; n  5) when compared with
untreated slices (to 55.6%; p	 0.01; n 11). Analogous results
were obtained in hippocampal cultures treated with cyclosporin
A (1 M, 60 min; to 100.5 7.5%; n 5), compared with cyclo-
sporin A untreated cultures (52 4%; n 5) (data not shown).
Our findings obtained with phosphatase inhibitors, together
with our data showing Ca2 dependency of CX3CL1 effects, led
us to investigate whether CX3CL1 might directly stimulate a
Ca2-dependent phosphatase activity. When hippocampal neu-
rons were stimulated with CX3CL1 either in the presence or ab-
sence of FSK, no change in PP2B-specific phosphatase activity
was observed (phosphatase assay, 2.52  0.43 pmol phosphate/
min/g of protein in untreated vs 2.56 0.37 in cells stimulated
with CX3CL1; 100 nM, 15 min) (data not shown).
Considered together, our data indicate that several factors,
including intracellular Ca2 andGi-dependent cAMP reduction,
were involved in the modulation of the CX3CL1-induced de-
crease of Ser845 phosphorylation and EPSC and AMPA current
depression. Importantly, our data are consistent with the effects
of CX3CL1 being mediated by changes in PKA rather than phos-
phatase activity.
Discussion
We report the effects of CX3CL1 on glutamatergic synaptic trans-
mission between Schaffer collaterals and CA1 pyramidal cells in
rat hippocampal slices. CX3CL1 reduces the amplitude of both
evoked whole-cell EPSCs and AMPA current responses by a
mechanism dependent on the modulation of postsynaptic
AMPA/KA receptors. CX3CL1 acts via a PTX-sensitive, Gi-
dependent reduction of intracellular cAMP, which in turn weak-
ens PKA-related phosphorylation of GluR1 Ser845, and favors
the action of phosphatases on this residue, thus promoting cur-
rent depression. Several pieces of experimental evidence support
this hypothesis: (1) CX3CL1 reduces FSK-induced cAMP accu-
mulation; (2) PTX abolishes CX3CL1 effects on EPSC amplitude,
cAMP accumulation, and Ser845 GluR1 phosphorylation; and
(3) both the displacement of PKA from AKAP79 with Ht31 and
the overcoming of AC inhibition with 8-Br-cAMP suppress
CX3CL1-mediated current depression. Furthermore, CX3CL1-
induced effects are coupled to phosphatase activity, because
blockers of protein phosphatases affect both CX3CL1-mediated
current depression and the reduction of Ser845 phosphorylation.
Finally, CX3CL1 action requires Ca
2 entry because EPSC de-
pression and the reduction of Ser845 phosphorylation are absent
when postsynaptic Ca2 is tightly controlled by the fast Ca2
chelator BAPTA and because the depression of AMPA current is
blocked in Ca2-free medium.
Postsynaptic site of EPSC depression
Our data support a postsynaptic site of action of CX3CL1 on
EPSC depression based on two pieces of evidence: (1) the absence
of changes in the paired-pulse ratio suggests an unchanged prob-
ability of transmitter release during chemokine application (Do-
brunz and Stevens, 1997), and (2) the reduction of the ampli-
tudes of spontaneous EPSCs and of AMPA currents by CX3CL1
treatment indicates decreased postsynaptic sensitivity. Our con-
clusion is in contrast to a previous report in cultured hippocam-
pal neurons, suggesting a presynaptic site for CX3CL1-induced
depression (Meucci et al., 1998). In addition, previous results
from our laboratory, showing that glutamatergic currents and
field EPSPs are depressed by CX3CL1 in hippocampal neurons
(Limatola et al., 2005; Bertollini et al., 2006). It is worthy to note
that the CX3CL1 doses used in our experiments (2–10 nM) are
much lower than those used byMeucci et al. (1998) and Oh et al.
(2002) (50–100 nM), leaving open the possibility that higher
doses could modulate other ion channels.
Ca2 and activity dependence of CX3CL1-induced
EPSC depression
CX3CL1-induced EPSC depression observed at the Schaffer
collateral-CA1 synapse is Ca2 dependent, because it is sup-
pressed when neurons are dialyzed with a high intracellular
BAPTA concentration (Glitsch et al., 2000). In addition, at low
BAPTA concentrations, EPSC and AMPA currents are depressed
more efficiently by CX3CL1 and without recovery. Although it
has been reported that CX3CL1 causes a transient intracellular
Ca2 rise in neurons (Meucci et al., 1998, 2000; Kansra et al.,
2001; Deiva et al., 2004), our results indicate that Ca2 release
Figure 7. CX3CL1 reduces FSK-induced cAMP accumulation coupled to EPSC depression. A,
Left, Time course of cAMP accumulation in cultured hippocampal neurons treated as indicated.
Untreated neurons, after 30min incubation, contained 0.17 pmol/gproteins. Right, Accumu-
lation of cAMP in cells treated for 15minwith FSK/CX3CL1 and pretreated as indicated. Data are
expressedas apercentageof cAMPaccumulation in cells stimulatedwith FSKalone. CX3CL1, 100
nM; FSK, 5.2M; pretreatment, BAPTA/AM, 5M, 1 h; PTX, 1g/ml, 2 h. B, Time course of the
effect of CX3CL1 application (horizontal bar, as indicated) on the amplitude of EPSC recorded in
CA1 pyramidal neurons in slices treated with FSK (F, 5M; n 10) or 8Br-cAMP (▫, 100M,
n 6). Either FSK or 8Br-cAMP superfusion started 20–40 min before applying CX3CL1.
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from intracellular stores does not play a
major role in the CX3CL1 effect, because
EPSCs are depressed by CX3CL1 when
neurons are dialyzed with the Ca2-
ATPase inhibitor thapsigargin. Further-
more, CX3CL1-induced depression of
AMPA currents generated by the activa-
tion of extrasynaptic receptors does not
develop when Ca2 is briefly withdrawn
during 10–50 ms AMPA applications,
suggesting that Ca2 influx is necessary to
activate current depression. Interestingly,
the fact that the slow Ca2 chelator EGTA
does not interfere with CX3CL1 effects
suggests that localized fast Ca2 transients
are required for AMPA receptor modula-
tion (Dargan and Parker, 2003).
We report that CX3CL1-induced gluta-
matergic depression does not develop in
the absence of coincident stimulation, and
AMPA currents are depressed by CX3CL1
treatment only after repetitive stimulation
of AMPA receptors. This is probably be-
cause of the fact that Ca2 influx is neces-
sary both for EPSC andAMPA current de-
pression. In our experimental conditions,
EPSCs still contain a small NMDA com-
ponent (Hestrin et al., 1990) that can con-
tribute substantially to Ca2 influx (Gara-
schuk et al., 1996). Nevertheless, a major
role of Ca2 entry through NMDA recep-
tors is unlikely, because the NMDA recep-
tor blocker D-APV did not influence the
CX3CL1-induced effects here reported.
Role of AC and phosphatases in
CX3CL1-induced depression
Synaptic plasticity in the hippocampus re-
quires a balance of protein kinase and
phosphatase activities (Colbran, 2004).
Because Ser845 GluR1 is a PKA target and
CX3CR1 activates Gi (Roche et al., 1996;
Al-Aoukaty et al., 1998), we speculate that
CX3CL1 impairs Ser845 phosphorylation by reducing PKA activ-
ity. This mechanism is consistent with the observations that: (1)
CX3CL1 reduces intracellular cAMP levels and Ser845 phosphor-
ylation, and these effects are blocked by PTX; (2) PTX inhibits
CX3CL1-mediated depression of EPSC; (3) CX3CL1 does not af-
fect EPSC after slice treatmentwith the stable cAMPanalog, 8-Br-
cAMP, mimicking irreversible AC activation or by intracellular
dialysis with Ht31, a peptide that detaches PKA from AKAP 79
(Tavalin et al., 2002; Snyder et al., 2005), preventing PKA-
dependent Ser845 phosphorylation.We conclude that the reduc-
tion of PKA activity favors the action of phosphatases, leading to
an impairment of GluR1 phosphorylation and current ampli-
tudes (Banke et al., 2000; Winder and Sweatt, 2001).
The critical role of protein phosphatases in CX3CL1-induced
current depression is further supported by the fact that EPSC
depression is absent when dephosphorylation is prevented by
ATPS or phosphatase inhibitors. It is likely that phosphatase
activity requires sustained synaptic Ca2 entry, as suggested by
EPSC depression blockade when intracellular Ca2 is tightly
buffered with BAPTA. It is unlikely that phosphatase activity is
Figure 8. CX3CL1 reduces GluR1 phoshorylation at Ser845 but not at Ser 831. A, Cell lysates from rat hippocampal slices treated as
indicated with FSK (15 min, 1M; left) or phorbol ester TPA (15 min, 1M; right) alone or together with CX3CL1 (100 nM), probed,
respectively, with anti-phosphoSer845 or anti-phosphoSer831 GluR1 and anti-actin antibodies and analyzed byWestern blot (represen-
tative of 11 and 3). B, Top, Cell lysates from HEK cells transiently expressing CX3CR1 and GluR1 analyzed as in A after 30 min of drug
treatment(representativeof10).Filmexposedfor30stoavoidsaturationsignals.Alongerexposureshowingmorepronouncedbasal level
of Ser845 phosphorylation is not illustrated. Bottom, Glutamate current traces fromHEK cells (representative of 10). Arrowheads, Gluta-
mate (200M) application. A cell treated with CX3CL1 (as indicated) for 7 min is shown. C, Top, Cell lysates from rat hippocampal cell
cultures treated as indicatedwith FSK (5min, 5.2M) alone or togetherwith CX3CL1 (100 nM) and analyzed as inA (representative of 4).
Bottom, Histogram of Ser845 phosphorylation in hippocampal neurons stimulated for 15 min as indicated. Data are expressed as a
percentage of Ser845 phosphorylation in cells stimulatedwith FSK/CX3CL1 versus FSK alone. CX3CL1, 100 nM; FSK, 5.2M; pretreatment,
BAPTA/AM, 5M, 1 h; PTX, 1g/ml, 2 h.
Figure 9. Calyculin A blocks CX3CL1-induced reduction of AMPA currents in hippocampal
slices. Time course of the effect of CX3CL1 on the amplitude of AMPA-evoked currents (100
pA) recorded in CA1 pyramidal neurons with calyculin A (▫, 100 nM, n 5) in the recording
pipette, compared with control (F, n 18).
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directly stimulated by CX3CL1, because no stimulation of PP2B
enzymatic activity by CX3CL1 was observed. The observation
that cell treatment with BAPTA-AM impairs the CX3CL1-
mediated reduction of Ser845 phosphorylation, but is ineffective
at reducing CX3CL1-mediated cAMP reduction, indicates that
Ca2-mediated basal phosphatase activity is necessary for this
effect. This scenario, that couples the phosphorylation state of
GluR1 Ser845 to CX3CL1-induced rundown of glutamate recep-
tor current (Tavalin et al. 2002; Snyder et al., 2005), shares many
properties with LTD (Lisman, 1989) and is supported by the
occlusion of CX3CL1-induced synaptic depression by the induc-
tion of homosynaptic LTD (Bertollini et al., 2006). Based on the
reported evidence, we propose that CX3CL1-induced signaling
shifts the balance between kinases and phosphatases acting on
Ser845 in favor of phosphatases by reducing PKA activity. Be-
cause the effects of CX3CL1 on current depression and phosphor-
ylation levels of Ser 845 require coincident Ca2 influx, we hy-
pothesize that, physiologically, CX3CL1 behaves as a modulator
of active glutamatergic synapses.
Physiological significance of CX3CR1 signaling in
the hippocampus
Several studies have shown that both CX3CL1 and its receptor
CX3CR1 are constitutively expressed in hippocampal neurons
(Hughes at al., 2002; Tarozzo et al., 2003). In cultured hippocam-
pal neurons, functional CX3CR1 is present (Meucci et al., 1998,
2000; Limatola et al., 2005), and its activation leads to G-protein-
sensitive signaling (Meucci et al., 2000). The CX3CL1-induced
synaptic modulation we report here is CX3CR1 dependent, be-
cause it is absent in CX3CR1 KO mice (Fig. 2). Furthermore,
CX3CL1-induced synaptic modulation is likely to be physiologi-
cally relevant, because its EC50 value is compatible with the
known chemotactic and neuroprotective effects of CX3CL1 (Li-
matola et al., 2005) and with the functional properties of cloned
CX3CR1 (Combadiere et al., 1998). In addition, the localized
synaptic effects of CX3CL1 are consistent with the diffuse expres-
sion of CX3CR1 on the soma (Hughes et al., 2002; Tarozzo et al.,
2003) and dendrites of hippocampal neurons (Meucci et al.,
2000; Limatola et al., 2005). Despite the known glial expression of
CX3CR1 (Harrison et al., 1998; Nishiyori et al., 1998), we ruled
out the possibility that exogenous CX3CL1 causes indirect EPSC
modulation through the glial release of other mediators, because
EPSC depression is exclusively postsynaptic and we did not ob-
serve significant changes in the membrane properties of CA1
pyramidal neurons, as would be predicted in the case of glia-
released neurotransmitters (Limatola et al., 2000; Ragozzino et
al., 2002). In support of this argument, we report that CX3CL1-
induced current depression also occurs in a reconstituted cell
expression system (Fig. 8B).
Our findings suggest that endogenous CX3CL1 is also likely to
modulate glutamatergic transmission via similar signalingmech-
anisms. However, the failure of CX3CL1 antibody to modulate
glutamatergic synaptic transmission suggests that the effect of
endogenous CX3CL1 may be not detectable under our experi-
mental conditions (although failure of the antibody to exhaus-
tively scavenge endogenous chemokine cannot be ruled out) and
disclosed only under conditions of physiological challenge, such
as cellular or tissue stress. Consistently, in the brain, soluble
CX3CL1 is generated on protease cleavage after multiple forms of
stimulation (Chapman et al., 2000; Tsou et al., 2001). Further-
more, we have shown previously that, in cultured hippocampal
neurons, CX3CL1 is released with a slow kinetics after prolonged
exposure to glutamate and it protects neurons from excitotoxic
cell death, suggesting a neuroprotective role for the chemokine
(Limatola et al., 2005). Thus, the glutamatergic inhibition de-
scribed here may contribute to CX3CL1 neuroprotective effects,
providing a feedback mechanism against excessive glutamate
exposure.
In conclusion, CX3CL1-dependent glutamatergic depression
represents a novel form of synaptic modulation in hippocampal
neurons. Fully understanding the impact of this modulation on
brain functionwill require additional experiments aimed at the in
vivo characterization of the functional effects of this chemokine
and, in particular, at ascertaining the possible pathophysiological
circumstances inducing its release.
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